Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Visualising Complex Data Results from 100,000 Cancer Patients

Published: Wednesday, December 12, 2012
Last Updated: Wednesday, December 12, 2012
Bookmark and Share
For decades, biomedical scientists have tried to develop a diagnostic tool for the early stages of cancer.

Earlier this week it was announced that up to 100,000 patients with cancer and rare diseases in England will have their entire genetic code sequenced, with the UK Prime Minister outlining that £100m has been set aside for the project over the next three to five years.

This is welcome news as for decades, biomedical scientists have been looking for new ways to diagnose cancers at an early, curable stage and also to select the optimal therapy for individual patients. At the moment, cancer treatments are effective in only some of the patients undergoing therapy, and many cancer patients are still being diagnosed too late, once the cancer is already too far advanced.  Despite these challenges, researchers are now exploring how unique biomarkers could help to improve the outcome for people with cancer by enhancing detection and treatment approaches.

However as with the 100,000 sample announced, mapping this kind of genetic data and performing genome sequencing in an attempt to try and personalise medical diagnosis and care, leads to enormous amounts of data being produced in order to classify patients into groups e.g. by distinctive biomarkers.

In addition, once you get to the clinical stage by taking DNA or blood samples even more data is produced and needed to be understand before patients can be grouped. Fortunately, in recent years there have been major developments in analysis software that can handle DNA mapping on this scale, helping to structure patients into groups and identifying which biomarkers should be used.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Qlucore, Nebion Collaborate
Partnership aims to address complementary use cases.
Friday, February 07, 2014
New Research Aims to Stop ‘Blood Doping' During Cycling and Other Competitive Sports
As cyclists take to the roads of Surrey, England, the subject of blood doping raises its head once again.
Thursday, August 01, 2013
New Biomarkers Could Offer Vital Clues for Cancer Research
European funding for cancer research has led to some interesting results in recent years, says Carl-Johan Ivarsson, CEO at Qlucore.
Friday, May 04, 2012
New Research Techniques Could Help to Eliminate the Need for Animal Testing
Carl-Johan Ivarsson, Qlucore, comments on the reducing necessity for animal models in today’s drug development industry, as research moves more towards in vitro analysis.
Monday, March 19, 2012
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!